Search
idarubicin; 4-methoxydaunorubicin (Idamycin)
Tradename: Idamycin.
Indications:
1) used in combination treatment of acute myeloid leukemia, including FAB classification M1-M7
2) non-Hodgkin's lymphoma
Powder for injection: (lyophilized) 5 mg, 10 mg.
Adverse effects:
1) common (> 10%)
- infection, nausea/vomiting, alopecia, diarrhea, hemorrhage, mucositis, reddish urine, fever, headache, leukopenia, thrombocytopenia
2) less common (1-10%)
- seizure, wheezing, peripheral neuropathy
3) uncommon (< 1%)
- myocardial toxicity, congestive heart failure, acute life-threatening arrhythmias
Test interactions:
- increased serum urea nitrogen, creatinine, AST, ALT, K+, uric acid
Interactions
drug interactions
drug adverse effects of anthracyclines
Related
daunorubicin, daunomycin; DNR (Cerubidine, DaunoXome)
General
anthracycline
Properties
INHIBITS: topoisomerase
MISC-INFO: pregnancy-category D
Database Correlations
PUBCHEM correlations
References
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Department of Veterans Affairs, VA National Formulary